Teva Pharmaceutical (TEVA) insider files Form 144 to sell 115,468 shares

Rhea-AI Filing Summary

Teva Pharmaceutical Industries reported a planned sale of restricted stock under Rule 144. The filing covers the potential sale of 115,468 ordinary shares through Citigroup Global Markets Inc. on the NYSE, with an aggregate market value of $3,311,131.04. The shares relate to ordinary shares acquired on 12/09/2025 via a cashless exercise of stock options, with cash noted as the form of payment.

The filing states that the person for whose account the securities may be sold represents that they are not aware of any material adverse, non-public information about Teva’s current or prospective operations.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
ORDINARY SHARES	CITIGROUP GLOBAL MARKETS INC 390 GREENWICH STREET NEW YORK NY 10013	115468	3311131.04	1147282512	12/09/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ORDINARY SHARES	12/09/2025	CASHLESS EXERCISE STOCK OPTIONS	TEVA PHARMACEUTICAL INDUSTRIES LIMITED			115468	12/09/2025	CASH

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Teva (TEVA) Form 144 filing disclose?

The filing discloses a planned Rule 144 sale of 115,468 Teva ordinary shares on the NYSE, with an aggregate market value of $3,311,131.04.

How were the Teva (TEVA) shares in this Form 144 acquired?

The 115,468 ordinary shares were acquired on 12/09/2025 through a cashless exercise of stock options, with cash listed as the nature of payment.

Which broker is handling the Teva (TEVA) Rule 144 share sale?

The planned sale is listed through Citigroup Global Markets Inc., located at 390 Greenwich Street, New York, NY 10013, and the shares are to be sold on the NYSE.

How many Teva (TEVA) shares are outstanding in this Form 144 disclosure?

The filing notes that the number of Teva ordinary shares outstanding is 1,147,282,512 at the time referenced in the form.

What representation does the seller make in this Teva (TEVA) Form 144?

The person for whose account the securities may be sold represents that they do not know any material adverse information about Teva’s current or prospective operations that has not been publicly disclosed.

What is the approximate date of sale in the Teva (TEVA) Form 144?

The approximate date of sale stated for the 115,468 ordinary shares is 12/09/2025.